By Colin Kellaher Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting .
By Colin Kellaher Bristol Myers Squibb on Thursday said it plans to cut more than 2,000 jobs as part of an initiative aimed at generating about $1.5 billion in cost savings by the end of next.
By Colin Kellaher Shares of ImmunityBio jumped more than 25% in premarket trading Tuesday after the immunotherapy company received Food and Drug Administration approval of its Anktiva.
By Colin Kellaher Nordson has hired Eaton executive Daniel Hopgood to succeed Joseph Kelley as the precision technology company s top finance executive. Nordson on Tuesday said Hopgood,.
By Colin Kellaher Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to bolster production of its cell therapies for type-1.